

Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value

Gang An,¹ Yan Xu,¹ Lihui Shi,¹ Shizhen, Zhong,¹ Shuhui Deng,² Zhenqing Xie,¹ Weiwei Sui,¹ Fenghuang Zhan,³ and Lugui Qiu^{1,2}

¹Department of Lymphoma and Myeloma, Institute of Hematology and Blood Diseases Hospital, State Key Laboratory of Experimental Hematology, Chinese Academy of Medical Sciences and Peking Union of Medical College, Tianjin, China; ²Umbilical Cord Blood Bank of Tianjin, China; and ³Department of Internal Medicine, Division of Hematology, Oncology, and Blood and Marrow Transplantation, University of Iowa, Iowa City, IA, USA

©2013 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2013.088211

Manuscript received on March 17, 2013. Manuscript accepted on August 8, 2013.

Correspondence: drqiu99@medmail.com.cn

Table S1: Patient characteristics in arm A and arm B

Characteristic	No. of patients/total no. (%)
Age (years)	
Median	57.0
Range	30-73
M component at diagnosis, %	
IgG	44/107(41.1)
IgA	32/107(29.9)
IgD	5/107(4.7)
Light chain	21/107(19.6)
Non-secretory	5/107(4.7)
β2- microglobulin	
<5.5mg/dl	52/107(48.6)
≥5.5mg/dl	55/107(51.4)
Cytogenetic abnormalities, %	
1q21 gains	
At least 3 copies of 1q21	68/102(66.7)
3 copies of 1q21	41/102(40.2)
At least 4 copies of 1q21	27/102(26.5)
del(13q)	59/107(55.1)
del(17p)	25/107(23.4)
IGH translocation	69/104(66.3)
t(11;14)	15/101(14.9)
t(4;14)	33/100(33.0)
t(14;16)	3/98(3.1)
High-risk[any t(4;14), t(14;16), or del(17p)]	51/100(51.0)
Treatment	
Thalidomide-based therapy	44/107(41.1)
Bortezomib-based therapy	63/107(58.9)
Abbreviations: ISS, International Staging System; Ig, immunoglobulin; DS, Durie Salmon; NS, no significant;	